Chao Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chao Ma has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey A. Meyerhardt
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA
72 shared publications - Pankaj Kumar
Department of Medical Oncology, Illinois CancerCare PC , Peoria, IL
70 shared publications - Qian Shi
Alliance Statistics and Data Management Center, Mayo Clinic , Rochester, MN
70 shared publications - Smitha Krishnamurthi
Cleveland Clinic, Cleveland, OH
70 shared publications - Eileen Mary O'Reilly
Weill Cornell Medicine
69 shared publications - Anthony F. Shields
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
68 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance)
Background: We sought to evaluate the associations of postdiagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial. Methods: We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months postrandom assignment. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (OS) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods. Results: Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not statistically significantly associated with survival outcomes, with a hazard ratio of 1.01 (95% CI = 0.75 to 1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate statistically significant associations with DFS or overall survival after Bonferroni correction. Conclusion: Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes. ClinicalTrials.gov identifier: NCT01150045.
- 21 October 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Open AccessFlavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance)
Background: We sought to evaluate the associations of postdiagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial. Methods: We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months postrandom assignment. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (OS) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods. Results: Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not statistically significantly associated with survival outcomes, with a hazard ratio of 1.01 (95% CI = 0.75 to 1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate statistically significant associations with DFS or overall survival after Bonferroni correction. Conclusion: Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes. ClinicalTrials.gov identifier: NCT01150045.
- 24 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Physical activity and molecular residual disease in stage III colon cancer: findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702
Background: Postoperative circulating tumor DNA (ctDNA) is a highly prognostic marker of residual disease among patients with stage III colon cancer, and physical activity has been associated with improved survival after curative resection. Whether physical activity predicts outcomes according to postoperative ctDNA status remains unknown. Methods: We conducted a post hoc analysis of Cancer and Leukemia Group B/SWOG 80702, a phase III study evaluating adjuvant celecoxib vs placebo and 3 vs 6 months of chemotherapy. Total physical activity volume was assessed using validated questionnaires and quantified in metabolic equivalent task hours per week (MET-h/week). Circulating tumor DNA status was determined using a clinically validated, tumor-informed assay (Signatera, Natera, Inc.). Results: Among 763 patients (median follow-up = 6.0 years), 32.3% were inactive ( .05 for all), though interactions were not statistically significant. Among patients who were physically active (≥9.0 MET-h/week) and received adjuvant celecoxib, improved DFS was observed in ctDNA-negative (HR = 0.41, 95% CI = 0.22 to 0.77) and ctDNA-positive (referent: inactive, placebo; HR = 0.29, 95% CI = 0.15 to 0.57) subgroups. Conclusions: Greater physical activity was associated with improved DFS among patients who were ctDNA-negative. Physical activity and adjuvant celecoxib were associated with favorable survival outcomes regardless of ctDNA status. Trial identifier: ClinicalTrials.gov NCT01150045
- 24 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Physical activity and molecular residual disease in stage III colon cancer: findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702
Background: Postoperative circulating tumor DNA (ctDNA) is a highly prognostic marker of residual disease among patients with stage III colon cancer, and physical activity has been associated with improved survival after curative resection. Whether physical activity predicts outcomes according to postoperative ctDNA status remains unknown. Methods: We conducted a post hoc analysis of Cancer and Leukemia Group B/SWOG 80702, a phase III study evaluating adjuvant celecoxib vs placebo and 3 vs 6 months of chemotherapy. Total physical activity volume was assessed using validated questionnaires and quantified in metabolic equivalent task hours per week (MET-h/week). Circulating tumor DNA status was determined using a clinically validated, tumor-informed assay (Signatera, Natera, Inc.). Results: Among 763 patients (median follow-up = 6.0 years), 32.3% were inactive ( .05 for all), though interactions were not statistically significant. Among patients who were physically active (≥9.0 MET-h/week) and received adjuvant celecoxib, improved DFS was observed in ctDNA-negative (HR = 0.41, 95% CI = 0.22 to 0.77) and ctDNA-positive (referent: inactive, placebo; HR = 0.29, 95% CI = 0.15 to 0.57) subgroups. Conclusions: Greater physical activity was associated with improved DFS among patients who were ctDNA-negative. Physical activity and adjuvant celecoxib were associated with favorable survival outcomes regardless of ctDNA status. Trial identifier: ClinicalTrials.gov NCT01150045
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S5. Hazard ratio of cancer-specific mortality by plasma 25-hydroxyvitamin D levels in plasma biomarker companion study and by predicted vitamin D scores in diet and lifestyle companion study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S5. Hazard ratio of cancer-specific mortality by plasma 25-hydroxyvitamin D levels in plasma biomarker companion study and by predicted vitamin D scores in diet and lifestyle companion study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S1. Baseline characteristics of study participants in the complete clinical trial, plasma biomarker companion study, and diet and lifestyle companion study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S1. Baseline characteristics of study participants in the complete clinical trial, plasma biomarker companion study, and diet and lifestyle companion study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S2. Dose-response relationship and test of linearity for the hazard ratio (HR) of disease-free survival (A), overall survival (B), and time to recurrence (C) by continuous predicted vitamin D scores, with reference of plasma 25-hydroxyvitamin D set at 12 ng/ml
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S2. Dose-response relationship and test of linearity for the hazard ratio (HR) of disease-free survival (A), overall survival (B), and time to recurrence (C) by continuous predicted vitamin D scores, with reference of plasma 25-hydroxyvitamin D set at 12 ng/ml
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S4. Hazard ratio of disease-free survival, overall survival, time to recurrence by quartiles of predicted vitamin D score
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S4. Hazard ratio of disease-free survival, overall survival, time to recurrence by quartiles of predicted vitamin D score
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S1. Diagram for study cohort derivation
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S1. Diagram for study cohort derivation
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus <12 ng/ml, across strata of potential effect modifiers
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus <12 ng/ml, across strata of potential effect modifiers